Portrait Published on 5 October 2016


Company : Horama

Job : President

Year of creation : 2014

Atlanpole : Your Business in brief: Denis CAYET :

Innovative biotechnology in the clinical phase through the development of a gene therapy platform, which targets genetic and rare diseases of the retina for which no solution currently exists.

A 1st product HORA-RPE65 was administered in humans with promising results for treating Leber’s amaurosis with a 3 years follow-up after treatment. A second product targeting retinitis pigmentosa will enter clinical trials in early 2017.

Horama’s team, originating from two research laboratories in Nantes and Montpellier, was the first in France to lead an eye gene therapy trial and produce a clinical batch of GMP adeno‑associated viral vectors.

Gene therapy dedicated to ophthalmology to restore visual function.
A. : What about your connection with the Ecosystem network? D. C. :

At the creation of Horama, Atlanpole brought us real support and assistance as well as many introductions to various partners. Since then, the Atlanpole Biotherapies cluster has helped us to participate in major international conferences in the best conditions and has provided real visibility to our new releases.

A. : Expected outcomes within 3 to 5 years? D. C. :

To provide therapeutic solutions to prevent blindness.

Number of employees

Back to Success stories